Skip to main content
Premium Trial:

Request an Annual Quote

Satoris, RayBiotech to Co-develop Alzheimer's Test

NEW YORK (GenomeWeb News) – Satoris will collaborate with RayBiotech to develop array-based test kits for Alzheimer's disease, the firms said today.

Satoris, a Redwood City, Calif.-based molecular diagnostics company that has developed a panel of 18 biomarkers that predicted the presence of Alzheimer's disease in test sample sets with up to 90 percent accuracy, will collaborate with RayBiotech, a developer and supplier of multiplex protein detection arrays and array-based test kits.

Under the collaboration, the 18 biomarkers will be applied to the RayBiotech Quantibody array platform. After the array-based test is validated for performance, it will be commercialized later this year as a research-use-only test. Norcross, Ga.-based RayBiotech will market the test, and Satoris will use the array along with proprietary bioinformatic analysis tools to offer a testing service.

"We expect this blood test will be well received as a valuable tool in Alzheimer's research and, potentially, as a diagnostic test as well," said Ray Huang, RayBiotech's president, in a statement. "Using antibody-based approaches, more biomarkers can be identified, validated, and put into clinical application faster and cheaper than with traditional methods based on mass spectrometry."

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.